Subjects underwent baseline nocturnal polysomnographic recording and ventilatory response tests (in a subgroup), and were subsequently commenced on hormone replacement therapy. These studies were repeated after 50 (3) days of treatment. Hormone replacement therapy consisted of oestrogen alone in those patients who had previously undergone hysterectomy (n = 6), and oestrogen plus progesterone in the rest (n = 9). Oestrogen treatment consisted of conjugated equine oestrogens (0-625 mg/day), oestradiol valerate (1 mg/day), or transdermal oestradiol (8 mg/week). Progesterone was administered as medroxyprogesterone acetate (2-5-10 mg/day).
Subjects underwent baseline nocturnal polysomnographic recording and ventilatory response tests (in a subgroup), and were subsequently commenced on hormone replacement therapy. These studies were repeated after 50 (3) days of treatment. Hormone replacement therapy consisted of oestrogen alone in those patients who had previously undergone hysterectomy (n = 6), and oestrogen plus progesterone in the rest (n = 9). Oestrogen treatment consisted of conjugated equine oestrogens (0-625 mg/day), oestradiol valerate (1 mg/day), or transdermal oestradiol (8 mg/week). Progesterone was administered as medroxyprogesterone acetate (2-5-10 mg/day).
Standard nocturnal polysomnography was performed as previously described by our laboratory.4 Calculated respiratory variables were the apnoea/hypopnoea index (number of apnoeas and hypopnoeas per hour of sleep), apnoea duration, and minimal oxygen saturation during apnoeas. Obstructive sleep apnoea was defined as an apnoea/hypopnoea index > 5. Apnoeas were defined as cessation of airflow for at least 10 seconds. Hypopnoea was defined as a reduction in amplitude of airflow or thoracoabdominal wall movement of greater than 50% of baseline for more than 10 seconds, associated with desaturation or arousal. These events were defined as obstructive if they occurred in association with continued diaphragm EMG activity and thoracoabdominal wall movement. Central events were defined as those accompanied by absence of diaphragm EMG activity and thoracoabdominal wall movement.
Hypoxic and hypercapnic ventilatory response tests were performed in 10 patients using previously described techniques.56 Hypoxic ventilatory response tests were performed at two end tidal carbon dioxide tensions -that is, resting end tidal CO2 (PETco2a) and an end tidal CO2 tension approximately 5 mm Hg higher (PETco2b). The relation between breath by breath ventilation and arterial oxygen saturation (Sao2) was calculated by linear regression for both PETCO2 values. The slope of these regression lines was then plotted against the PETCO2 value at which the test was performed. Hypoxic ventilatory response was expressed by the formula described by Slutsky et al:78 hypoxic sensitivity = dV/dSao2 = k,.Pco2 + k2 where k, represents the slope of the slopes of ventilation (V) v Sao2 at the Pco2 at which hypoxia was induced, and k2 is they intercept. This formula expresses a differential change in response for a given differential change in stimulus, and allows comparisons between individuals with different Pco2 levels and within individuals for different levels of Pco2. The recognition of a male preponderance in the prevalence of sleep apnoea, and an increasing prevalence in women after the menopause, has led to speculation that hormonal factors may influence the pathogenesis of sleep apnoea. A number of studies have suggested that androgens may adversely affect sleep disordered breathing in both men and women.9 10 However, androgen blockade does not reduce sleep apnoea in men with moderate to severe sleep apnoea." The low prevalence of sleep apnoea in premenopausal women and the increasing frequency after menopause has stimulated interest in the effect of female sex hormones on sleep and breathing. Pickett et a12 investigated respiration during sleep in nine healthy postmenopausal women after one week of treatment with combined oestrogen and progesterone or placebo. Mild sleep apnoea was observed in patients receiving placebo (apnoea/hypopnoea index 15 (4)), which decreased following treatment with oestrogen and progesterone to 3 (1). Despite these changes no difference in sleep architecture or arousals, and only minimal decreases in mean apnoea/hypopnoea duration, were observed between medication and placebo. Because of the impressive decrease in the apnoea/hypopnoea index after combined hormone treatment reported in that study, and a case report of the effectiveness of combined treatment in more severe sleep apnoea,3 we proceeded to examine the effect of conventional dose oestrogen and progesterone replacement in postmenopausal patients presenting with moderate to severe forms of sleep apnoea. Our negative findings strongly suggest that conventional hormone replacement therapy is not a treatment alternative for postmenopausal women with sleep apnoea.
A number of factors may explain the discrepancy between the results of our study and those of the previous reports. Most patients in our study were obese and this, rather than changes in hormone levels, is likely to be the dominant factor in producing apnoea. The subjects studied by Pickett et a12 were all of normal weight with no reported history of sleep apnoea. High, non-conventional doses of oestrogen and progesterone were used in their study (medroxyprogesterone acetate 20 mg three times daily and conjugated equine oestrogens, Premarin, 1 25 mg twice daily), and these are likely to be associated with significant side effects precluding their clinical use. Our study was open and not placebo controlled, so it is possible that a therapeutic effect of hormone replacement may have been obscured by a "first night effect" leading to reduced apnoea severity at baseline. We feel this is unlikely as patients had similar sleep architecture in both studies.
We did note a small but clinically insignificant reduction in the apnoea/hypopnoea index during REM sleep, despite no change in the absolute amount of REM sleep. There were also some individuals with a clinically significant fall in the apnoea/hypopnoea index but this did not correlate with the increment in serum oestrogen level following treatment. It is possible, therefore, that some individuals may well have a therapeutic response to oestrogen and progesterone, but in general the effect of hormone replacement on sleep apnoea was disappointing.
Sex hormones influence ventilatory control which, in turn, may affect sleep apnoea. Progesterone is known to stimulate ventilation and increase chemosensitivity during the luteal phase of the menstrual cycle,'2 in pregnancy,'3 and in normal men.'415 Progesterone can improve ventilation in patients with alveolar hypoventilation,'6 but its effects on the degree of sleep apnoea in men'7 are relatively minor. Goodman et al'8 found that the ventilatory stimulation induced by progesterone was prolonged in the presence of oestrogen. Maximum stimulation of ventilation by progesterone has been shown to occur after seven days, with initial effects at 48 hours. ' 9 Surprisingly, we were unable to show a significant change in the hypercapnic ventilatory response in our patients after 50 (3) days of treatment, even in those receiving progesterone. It is likely that this relates to the lower doses used in our study compared with previous studies. In contrast, the hypoxic ventilatory response did increase. Despite a tendency for PETCO2 levels to be lower after hormone replacement, there was a significant increase in the slope of sensitivity v Pco2 (k,) indicating a larger interactive component with carbon dioxide. The significance of this finding in the absence of any major change in apnoea is uncertain. It is possible, however, that this change in hypoxic responsiveness might relate to the improved apnoea in REM. Although there are conflicting data from animal and human studies, at least one study suggests that the hypoxic reflex system plays a relatively more important part in REM sleep.20
In summary, our data indicate that short term hormone replacement therapy in conventional doses does not significantly reduce the clinical severity of obstructive sleep apnoea in postmenopausal women. It is possible that higher doses or longer treatment may influence sleep apnoea in some individuals but, in general, sleep disordered breathing does not appear to be related simply to low levels of oestrogen and progesterone.
